A Study in Subjects With Human Papillomavirus 16 or 18 Associated Cervical Intraepithelial Neoplasia Grade 2 or 3
The purpose of this study is to to evaluate the safety, tolerability, immunogenicity, and efficacy of RG002 Injection in subjects with HPV16/18 associated Cervical Intraepithelial Neoplasia Grade 2 or 3(CIN2/3).
Human Papillomavirus Associated Intraepithelial Neoplasia|Cervical Intraepithelial Neoplasia Grade 2/3|Human Papillomavirus Type 16 Infection|Human Papillomavirus Type 18 Infection
BIOLOGICAL: RG002 injection
Part A: Safety and Tolerability of RG002 Injection, measured by the incidence of adverse events, Safety and Tolerability of RG002 Injection will be measured by the incidence of adverse events per CTCAE v5.0, Week 9|Part A: Maximum tolerated dose (MTD) and/or RP2D of RG002 Injection, MTD:Week 9; RP2D: Week 36|Part B: Primary efficacy of RG002 Injection, measured by the proportion of subjects with histopathological regression, The proportion of subjects with histopathological regression to either CIN1 or normal at Week 36, Week36
Part A: Preliminary efficacy of RG002 Injection,measured by proportion of subjects with histopathological regression, The proportion of subjects with histopathological regression to either CIN1 or normal at Week 36, Week36|Part A: Preliminary efficacy of RG002 Injection,measured by proportion of subjects with clearance of HPV16/18, The clearance of HPV16 or HPV18 will be evaluated according to the results of HPV test at Week 21 and Week 36., Week36|Part A: Preliminary efficacy of RG002 Injection,measured by proportion of subjects with histopathological regression and clearance of HPV16/18, The proportion of subjects with histopathological regression to CIN1 or normal and clearance of HPV16 or HPV18, or both at Week36., Week36|Part A and B: Immunogenicity of RG002 Injection,measured by the level of cellular immune response, The level of cellular immune response in Peripheral blood mononuclear cells (PBMCs) as measured by IFN-γ enzyme-linked immunosorbent spot-forming (ELISpot) assay, Week36|Part A and B: Immunogenicity of RG002 Injection,measured by the proportion of T lymphocytes, The immuno-phenotyping including the proportion of CD3+CD4+CD137+ and CD3+CD8+CD137+ T lymphocytes in whole blood as measured by flow cytometry., Week36|Part A and B: Immunogenicity of RG002 Injection,measured by the expression of cytokines in serum, The expression of cytokines in serum, i.e., IL-1β, IL-1ra, IL-2, IL-6, IL-10, GM-CSF, TNF-α and IFN-γ measured by MSD® Assays., Week36|Part A and B: Immunogenicity of RG002 Injection,measured by the serum levels of anti-HPV16 and anti-HPV18 IgG antibodies., Serum levels of anti-HPV16 and anti-HPV18 IgG antibodies as measured by Luminex., Week36|Part A and B: Exposure level of RG002 Injection, measured by mRNA, The plasma exposure level(AUC, Cmax, etc.) of mRNA will be measured Real Time Quantitative-Polymerase Chain Reaction (RT-qPCR), Week7|Part A and B: Exposure level of RG002 Injection, measured by cationic lipids, The plasma exposure level(AUC, Cmax, etc.) of cationic lipids will be measured by Liquid Chromatography Tandem Mass Spectrometry(LC-MS/MS)., Week7|Part A and B: Anti-drug antibody (ADA) to polyethylene glycol (PEG) of RG002 injection, measured by the serum titer of anti-PEG IgG and anti-PEG IgM, The serum titer of anti-PEG IgG and anti-PEG IgM as measured by enzyme-linked immunosorbent assay (ELISA)., Week6|Part B: Secondary efficacy, measured by proportion of subjects with histopathological regression, The proportion of subjects with histopathological regression to either CIN1 or normal at Week 36, Week36|Part B: Secondary efficacy, measured by proportion of subjects with clearance of HPV16/18, The clearance of HPV16 or HPV18 will be evaluated according to the results of HPV test at Week 21 and Week 36., Week36|Part B: Secondary efficacy, measured by proportion of subjects with histopathological regression and clearance of HPV16/18, The proportion of subjects with histopathological regression to CIN1 or normal and clearance of HPV16 or HPV18, or both at Week36., Week36|Part B: Safety and tolerability of RG002 Injection, measured by the incidence of adverse events, Safety and Tolerability of RG002 Injection will be measured by the incidence of adverse events per CTCAE v5.0, Week9|Part B: Optionally assess the biomarker of RG002 Injection, measured by the level of potential biomarkers and the level of infiltrating T cells and myeloid cells in the lesions., The level of potential biomarkers of RG002 Injection, i.e., CD45, CD3, CD4, CD8, CD25, FOXP3, PD-1, and CD137, and the level of infiltrating T cells (CD3, CD8, FOXP3, TIM3, Tbet, PD-1, DAPI) and myeloid cells (CD14, CD33, CD68, CD163, CD11c, PD-L1, DAPI) in the lesions., Week36
The purpose of this study is to to evaluate the safety, tolerability, immunogenicity, and efficacy of RG002 Injection in subjects with HPV16/18 associated Cervical Intraepithelial Neoplasia Grade 2 or 3(CIN2/3).